Abstract

1. Abstract
Immune checkpoint inhibitors (PD-1 inhibitors) are extensively used in cancer treatment. These inhibitors have exhibited definite curative effects in non-small cell lung cancer, Hodgkin's lymphoma, hepatocellular carcinoma, and oesophageal squamous cell carcinoma. However, no comprehensive study has been conducted to evaluate the clinical efficacy of PD-1 inhibitors in the treatment of gestational trophoblastic tumours. A 54-year-old female patient presented with advanced choriocarcinoma and multiple systemic metastases with urinary blood after failed multiline chemotherapy. The clinical survival time was predicted to be approximately 1 month. However, the patient condition was partially relieved after administration of immunotherapy with the PD-1 inhibitor toropalimab. The patient returned to normal life, which confirms the efficacy of the PD-1 inhibitor. In conclusion, although toropalimab has no relevant indications for choriocarcinoma, it can improve patient survival under certain conditions.